Drugs / tegafur, Gimeracil and Oteracil Potassium
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07643623 Background | Jun 2026 → Dec 2031 expected | adenocarcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tegafur, Gimeracil and Oteracil Potassium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07643623 ↗ |
| Route | Oral | “40mg/m2, D1-14 BID PO Q3W” NCT07643623 ↗ |